- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02121860
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
January 27, 2016 updated by: Conatus Pharmaceuticals Inc.
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with mild, moderate, and severe hepatic impairment (defined as Child-Pugh A, B, and C, respectively) and matched healthy volunteers with normal hepatic function.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
DeLand, Florida, United States, 32720
- Avail Clinical Research
-
Miami, Florida, United States, 33136
- University of Miami
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
All Subjects:
- Male or female subjects 18 years of age or older, able to provide written informed consent, understand and comply with all scheduled visits, and other requirements of the study
- Body mass index (BMI) 18.0 - 40.0 kg/m2 and body weight >45 kg
- Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug
Matched Healthy Volunteers:
- Medically healthy as determined by the Investigator
- Supine blood pressure ≤145/90 mmHg
- No significant uncontrolled systemic or major illness that, in the opinion of the Investigator, would preclude the subject from participating in and completing the study
Demographically comparable to subjects with hepatic impairment as follows:
- Mean body weight within ±15 kg
- Mean age within ±10 years
- Similar gender ratio
Subjects with Hepatic Impairment:
Evidence of hepatic disease
- Score ≥ 2 on one of the Child-Pugh parameters, or
- Histological or imaging diagnosis of cirrhosis, or
- Presence of esophageal varices, or
- Abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) levels
Meet one of the following criteria for Child-Pugh classification for hepatic impairment during Screening
- Mild hepatic impairment: Class A (Child-Pugh Scores 5-6 points)
- Moderate hepatic impairment: Class B (Child-Pugh Scores 7-9 points)
- Severe hepatic impairment: Class C (Child Pugh Scores 10-15 points)
- Supine blood pressure ≤160/100 mmHg
Exclusion Criteria:
All Subjects:
- Known infection with human immunodeficiency virus (HIV) upon serological testing
- Evidence of clinically significant uncontrolled hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
- Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.)
- History of febrile illness within 5 days prior to dosing Note: Subjects can be rescreened once afebrile and more than 5 days have elapsed since the febrile illness.
- Known ongoing drug abuse within one month prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during Screening and/or at Day -1
- Subjects with active or history of malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)
- Dosing in another clinical trial within 30 days prior to the study drug administration
- If female: known pregnancy, positive urine or serum pregnancy test, or lactating/breastfeeding
Matched Healthy Volunteers:
- Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease, elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is considered clinically significant by the Investigator, etc.)
- Screening creatinine clearance <80 mL/min using the Cockcroft-Gault equation
- History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of >450 milliseconds (msec)
- History of regular alcohol consumption exceeding 28 drinks/week (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of spirits) within 6 months of Screening
Subjects with Hepatic Impairment:
- Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment during Screening period and up to Day -1 (e.g., advanced ascites, infection of ascites, fever, active gastrointestinal bleeding)
- History of liver transplant, or have a transjugular intrahepatic portosystemic shunt, and/or have undergone portacaval shunting
- History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of >480 milliseconds (msec)
- Screening creatinine clearance <50 mL/min using the Cockcroft-Gault equation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chil-Pugh Class A
All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
|
Other Names:
|
Experimental: Chil-Pugh Class B
All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
|
Other Names:
|
Experimental: Chil-Pugh Class C
All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
|
Other Names:
|
Experimental: Normal Hepatic Function
All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: 48 Hours
|
Area under the plasma concentration curve (AUC) to 12 hours post-dose (AUC0-12); AUC to the last observed plasma concentration (AUClast);
|
48 Hours
|
Cmax
Time Frame: 48 Hours
|
Maximum concentration (Cmax)
|
48 Hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of cCK18/M30
Time Frame: predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose
|
Caspase-cleaved cytokeratin levels (cCK18M30)
|
predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose
|
Levels of Caspase 3/7 RLU
Time Frame: predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose
|
Concentration of Caspase 3/7 Relative Light Units
|
predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Dave Hagerty, MD, Conatus Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
July 1, 2014
Study Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
April 18, 2014
First Submitted That Met QC Criteria
April 22, 2014
First Posted (Estimate)
April 24, 2014
Study Record Updates
Last Update Posted (Estimate)
February 24, 2016
Last Update Submitted That Met QC Criteria
January 27, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDN-6556-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Medical College of WisconsinRecruiting
-
Taipei City HospitalThe One Biopharmaceutical Co., Ltd.CompletedNon-alcoholic Fatty Liver Disease | Liver Fibrosis | Liver InjuryTaiwan
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
-
Assiut UniversityNot yet recruiting
Clinical Trials on IDN-6556
-
University of AlbertaConatus Pharmaceuticals Inc.Completed
-
Conatus Pharmaceuticals Inc.Idun PharmaceuticalsCompleted
-
Conatus Pharmaceuticals Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA)TerminatedAlcoholic HepatitisUnited States
-
Conatus Pharmaceuticals Inc.CompletedKidney Diseases | Renal Insufficiency | Renal Impairment | Kidney DiseaseUnited States
-
Conatus Pharmaceuticals Inc.CompletedLiver Diseases | Fibrosis | Non-alcoholic SteatohepatitisUnited States, Spain, Germany
-
Conatus Pharmaceuticals Inc.CompletedLiver Cirrhosis | Portal Hypertension | Hepatic CirrhosisUnited States
-
Conatus Pharmaceuticals Inc.Idun PharmaceuticalsCompletedLiver Transplantation | Hepatitis | Carcinoma, Hepatocellular | CholestasisUnited States, Germany
-
Conatus Pharmaceuticals Inc.TerminatedLiver Cirrhosis | Acute on Chronic Hepatic Failure | Acute Liver Failure | Acute Alcoholic HepatitisUnited States, United Kingdom
-
Conatus Pharmaceuticals Inc.CompletedLiver Cirrhosis | Hepatic CirrhosisUnited States
-
Conatus Pharmaceuticals Inc.CompletedLiver Cirrhosis | Hepatic Fibrosis | Liver Fibrosis | Hepatic CirrhosisUnited States